title: HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.
abstract: We developed a candidate DNA vaccine designated pCMV160IIIB with pcREV (pCMV160IIIB/REV) that encodes gp160 of human immunodeficiency virus (HIV)-1IIIB and Rev driven by the cytomegalovirus (CMV) promotor. This vaccine induced both HIV-1-specific antibodies and cytotoxic T lymphocyte (CTL) activity. In the present study, we inoculated the TCA3 expression plasmid into mouse skeletal muscle with pCMV160IIIB/REV to determine whether this cytokine expression plasmid was able to modify the immune response. Results of a delayed-type hypersensitivity (DTH) assay using footpad swelling as well as those of a CTL assay clearly demonstrated that cell-mediated immunity (CMI) elicited by co-inoculation of pCMV160IIIB/REV with the TCA3 expression plasmid was markedly enhanced compared with that obtained using pCMV160IIIB/REV alone. When TCA3 expression plasmid was inoculated with anti-TCA3 antibody, enhancement of the DTH response was suppressed below the level of that obtained with pCMV160IIIB/REV alone. The titre of HIV-1-specific IgG2a was slightly high when pCMV160IIIB/REV was co-inoculated with this plasmid, suggesting that T-helper 1 (Th1) response was predominant in TCA3-inoculated mice. Infiltration of mononuclear cells was seen in the muscles at sites where TCA3 expression plasmid had been inoculated. Our present data suggest that TCA3 expression plasmid has potent adjuvant activity that results in an augmented CMI response.
authors.affiliation: Department of Bacteriology, Yokohama City University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
authors.forename: J
authors.initials: J
authors.lastname: Fukushima
authors.forename: K
authors.initials: K
authors.lastname: Hamajima
authors.forename: N
authors.initials: N
authors.lastname: Ishii
authors.forename: I
authors.initials: I
authors.lastname: Aoki
authors.forename: H
authors.initials: H
authors.lastname: Bukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ishigatsubo
authors.forename: K
authors.initials: K
authors.lastname: Tani
authors.forename: T
authors.initials: T
authors.lastname: Okubo
authors.forename: M E
authors.initials: ME
authors.lastname: Dorf
authors.forename: K
authors.initials: K
authors.lastname: Okuda
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000818:Animals; D054402:Chemokine CCL1; D019742:Chemokines, CC; D016207:Cytokines / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005260:Female; D015483:HIV Antibodies / Q000096:biosynthesis; D015497:HIV-1 / Q000276:immunology*; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D051379:Mice; D008807:Mice, Inbred BALB C; D009132:Muscles / Q000276:immunology; D010957:Plasmids; D054401:Receptors, CCR8; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; C065971:CCL1 protein, human; C489319:Ccr8 protein, mouse; D054402:Chemokine CCL1; D019742:Chemokines, CC; D016207:Cytokines; D015483:HIV Antibodies; D054401:Receptors, CCR8; D019444:Vaccines, DNA